In the Stem Cell Jungle

@UCu7erUAVT2hMmc0m0qiPAkw - 332 subscribers

Sit back, grab a drink, and watch world-class experts discuss hot topics about stem cells and their applications !

Home Videos Live Playlists

What are the limitations of the C-Stem™ platform?

What are the limitations of the C-Stem™ platform? In the Stem Cell Jungle

156 views - 3 years ago

What does the C-Stem™ platform bring to the cell therapy field?

What does the C-Stem™ platform bring to the cell therapy field? In the Stem Cell Jungle

145 views - 3 years ago

Is it possible to differentiate hiPSCs into any cell type in C-Stem™?

Is it possible to differentiate hiPSCs into any cell type in C-Stem™? In the Stem Cell Jungle

95 views - 3 years ago

Encapsulating pluripotent stem cells: why ?

Encapsulating pluripotent stem cells: why ? In the Stem Cell Jungle

171 views - 3 years ago

Why does C-Stem™ preserve genomic integrity?

Why does C-Stem™ preserve genomic integrity? In the Stem Cell Jungle

130 views - 3 years ago

How does C-Stem™ achieve almost 300-fold hiPSC expansion within a week?

How does C-Stem™ achieve almost 300-fold hiPSC expansion within a week? In the Stem Cell Jungle

162 views - 3 years ago

INDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process

INDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process In the Stem Cell Jungle

43 views - 3 years ago

Off-the-shelf T and NK cells : benefits of allogeneic strategies in immuno-oncology

Off-the-shelf T and NK cells : benefits of allogeneic strategies in immuno-oncology In the Stem Cell Jungle

65 views - 3 years ago

The challenge of targeting solid tumors with T cells I TIL therapies I TCR Ts

The challenge of targeting solid tumors with T cells I TIL therapies I TCR Ts In the Stem Cell Jungle

340 views - 3 years ago

Cell therapies in Immuno-Oncology : from Academia to Big Pharma

Cell therapies in Immuno-Oncology : from Academia to Big Pharma In the Stem Cell Jungle

44 views - 3 years ago

Filling gaps of autologous CAR-T : opportunities and challenges of allogeneic cell therapies

Filling gaps of autologous CAR-T : opportunities and challenges of allogeneic cell therapies In the Stem Cell Jungle

24 views - 3 years ago

The promise of NK cells in immuno-oncology I Mode of Action I Comparison with Ts I Safety profile In the Stem Cell Jungle

35 views - 3 years ago

iPSC-derived NK cells versus T cells : differentiation, amplification, in vivo function

iPSC-derived NK cells versus T cells : differentiation, amplification, in vivo function In the Stem Cell Jungle

293 views - 3 years ago

The promise of allogeneic T and NK cells in immuno-oncology | Neil Sheppard | Stem Cell Jungle

The promise of allogeneic T and NK cells in immuno-oncology | Neil Sheppard | Stem Cell Jungle In the Stem Cell Jungle

673 views - 3 years ago

Tissue-resident immune cells – a key lever in any pathology ? Miriam Merad | In The Stem Cell Jungle

Tissue-resident immune cells – a key lever in any pathology ? Miriam Merad | In The Stem Cell Jungle In the Stem Cell Jungle

178 views - 4 years ago

Tissue resident immune cells in cancer – friends or foes ? Miriam Merad | In The Stem Cell Jungle

Tissue resident immune cells in cancer – friends or foes ? Miriam Merad | In The Stem Cell Jungle In the Stem Cell Jungle

107 views - 4 years ago

Discovery : a lineage of tissue-resident macrophages independent from the monocyte lineage

Discovery : a lineage of tissue-resident macrophages independent from the monocyte lineage In the Stem Cell Jungle

177 views - 4 years ago

Alzheimer’s disease – a disease linked to the loss of tissue-resident macrophages ? Miriam Merad

Alzheimer’s disease – a disease linked to the loss of tissue-resident macrophages ? Miriam Merad In the Stem Cell Jungle

49 views - 4 years ago

Enhancing CAR-T cell activity with tissue resident immune cells | Miriam Merad | Stem Cell Jungle

Enhancing CAR-T cell activity with tissue resident immune cells | Miriam Merad | Stem Cell Jungle In the Stem Cell Jungle

103 views - 4 years ago

CAR-macrophages – a potential slippery slope ? Miriam Merad | In The Stem Cell Jungle

CAR-macrophages – a potential slippery slope ? Miriam Merad | In The Stem Cell Jungle In the Stem Cell Jungle

308 views - 4 years ago

Immuno-oncology: Reprogramming tissue-resident immune cells in vivo with mRNA | Miriam Merad

Immuno-oncology: Reprogramming tissue-resident immune cells in vivo with mRNA | Miriam Merad In the Stem Cell Jungle

53 views - 4 years ago

What role for tissue-resident immune cells in immuno-oncology & regenerative medicine ? Miriam Merad

What role for tissue-resident immune cells in immuno-oncology & regenerative medicine ? Miriam Merad In the Stem Cell Jungle

297 views - 4 years ago

Cell therapy for AMD – different strokes for different folks ? | Masayo Takahashi

Cell therapy for AMD – different strokes for different folks ? | Masayo Takahashi In the Stem Cell Jungle

89 views - 4 years ago

Surgical capacities – a limit for the cell therapy market ? | Masayo Takahashi | Stem Cell Jungle

Surgical capacities – a limit for the cell therapy market ? | Masayo Takahashi | Stem Cell Jungle In the Stem Cell Jungle

60 views - 4 years ago

Cell therapy development in Japan vs USA | Masayo Takahashi | In the Stem Cell Jungle

Cell therapy development in Japan vs USA | Masayo Takahashi | In the Stem Cell Jungle In the Stem Cell Jungle

1.2K views - 4 years ago

Blending cell therapy and gene editing in ophthalmology | Masayo Takahashi | In the Stem Cell Jungle

Blending cell therapy and gene editing in ophthalmology | Masayo Takahashi | In the Stem Cell Jungle In the Stem Cell Jungle

58 views - 4 years ago

Autologous iPSCs as a life-time resource for regenerative medicine – The CiRA's strategy

Autologous iPSCs as a life-time resource for regenerative medicine – The CiRA's strategy In the Stem Cell Jungle

25 views - 4 years ago

Do we need different toxicity tests with cell therapy products ? | Masayo Takahashi

Do we need different toxicity tests with cell therapy products ? | Masayo Takahashi In the Stem Cell Jungle

48 views - 4 years ago

What are the specificities of cell therapy development ? | Masayo Takahashi | Stem Cell Jungle

What are the specificities of cell therapy development ? | Masayo Takahashi | Stem Cell Jungle In the Stem Cell Jungle

353 views - 4 years ago

Cell therapies for Parkinson's disease: the perspective of Parkinson's UK

Cell therapies for Parkinson's disease: the perspective of Parkinson's UK In the Stem Cell Jungle

3.6K views - 4 years ago

CAR-Ts, NKs, Gene editing: Past, Present and Future of Cell Therapies for Immuno-Oncology

CAR-Ts, NKs, Gene editing: Past, Present and Future of Cell Therapies for Immuno-Oncology In the Stem Cell Jungle

329 views - 4 years ago

Philosophical Analysis of the Concept of Stemness I Lucie Laplane, PhD I In the Stem Cell Jungle

Philosophical Analysis of the Concept of Stemness I Lucie Laplane, PhD I In the Stem Cell Jungle In the Stem Cell Jungle

145 views - 4 years ago

Automation of cell therapy manufacturing processes - with Jon Ellis, Invetech

Automation of cell therapy manufacturing processes - with Jon Ellis, Invetech In the Stem Cell Jungle

143 views - 4 years ago

Quality control of iPS-derived cell therapy in Japan I With Prof. Shin Kawamata

Quality control of iPS-derived cell therapy in Japan I With Prof. Shin Kawamata In the Stem Cell Jungle

180 views - 4 years ago

Stem cell therapies from an investor perspective - Alasdair Thong, Early Stage Healthcare Investor

Stem cell therapies from an investor perspective - Alasdair Thong, Early Stage Healthcare Investor In the Stem Cell Jungle

100 views - 4 years ago

Stem Cell Therapies for Diabetes - In The Stem Cell Jungle with Albert Hwa

Stem Cell Therapies for Diabetes - In The Stem Cell Jungle with Albert Hwa In the Stem Cell Jungle

602 views - 4 years ago

Laurence Daheron, HSCI - Head of IPS Core Facility - Harvard Stem Cell Institute

Laurence Daheron, HSCI - Head of IPS Core Facility - Harvard Stem Cell Institute In the Stem Cell Jungle

185 views - 4 years ago

What are the benefits of culturing pluripotent stem cells in 3D epiblast conformation ?

What are the benefits of culturing pluripotent stem cells in 3D epiblast conformation ? In the Stem Cell Jungle

309 views - 4 years ago

Are we living a golden era in stem cell biology ? | Marta Shahbazi | In the Stem Cell Jungle

Are we living a golden era in stem cell biology ? | Marta Shahbazi | In the Stem Cell Jungle In the Stem Cell Jungle

83 views - 4 years ago

Stem cells in 2D vs 3D : a 2,500-fold difference in the concentration of autocrine factors

Stem cells in 2D vs 3D : a 2,500-fold difference in the concentration of autocrine factors In the Stem Cell Jungle

35 views - 4 years ago

How does 3D organization influence stem cell differentiation ? | In the Stem Cell Jungle

How does 3D organization influence stem cell differentiation ? | In the Stem Cell Jungle In the Stem Cell Jungle

29 views - 4 years ago

Overcoming variability accross stem cell lines… by mimicking developmental biology mechanisms ?

Overcoming variability accross stem cell lines… by mimicking developmental biology mechanisms ? In the Stem Cell Jungle

23 views - 4 years ago

Reduced genetic abnormalities with iPS cells cultured in 3D ? | In the Stem Cell Jungle

Reduced genetic abnormalities with iPS cells cultured in 3D ? | In the Stem Cell Jungle In the Stem Cell Jungle

17 views - 4 years ago

Becoming a PI : management vs experiments ? The LMB model | Marta Shahbazi

Becoming a PI : management vs experiments ? The LMB model | Marta Shahbazi In the Stem Cell Jungle

93 views - 4 years ago

Cell therapy for Parkinson’s disease : allogeneic or autologous ?

Cell therapy for Parkinson’s disease : allogeneic or autologous ? In the Stem Cell Jungle

133 views - 4 years ago

How long ? Do patients have to wait for the effects of cell therapies for Parkinson's disease ?

How long ? Do patients have to wait for the effects of cell therapies for Parkinson's disease ? In the Stem Cell Jungle

57 views - 4 years ago

How promising are the most recent results of cell therapies for Parkinson’s disease ?

How promising are the most recent results of cell therapies for Parkinson’s disease ? In the Stem Cell Jungle

259 views - 4 years ago

Affordable cell therapies for Parkinson’s disease ?

Affordable cell therapies for Parkinson’s disease ? In the Stem Cell Jungle

53 views - 4 years ago

Can cell therapies address non-motor symptoms in Parkinson’s disease ?

Can cell therapies address non-motor symptoms in Parkinson’s disease ? In the Stem Cell Jungle

31 views - 4 years ago

Cell therapy for Parkinson's disease: Are rodent studies sufficient before clinical trials ?

Cell therapy for Parkinson's disease: Are rodent studies sufficient before clinical trials ? In the Stem Cell Jungle

79 views - 4 years ago

Autologous CAR-T cell therapy: manufacturing issues

Autologous CAR-T cell therapy: manufacturing issues In the Stem Cell Jungle

155 views - 4 years ago

Allogeneic CAR-T cells: for hematological malignancies and solid tumors ?

Allogeneic CAR-T cells: for hematological malignancies and solid tumors ? In the Stem Cell Jungle

159 views - 4 years ago

NK cells: a silver bullet to target solid tumors ?

NK cells: a silver bullet to target solid tumors ? In the Stem Cell Jungle

84 views - 4 years ago

Multiplexed gene editing & CAR-T cells: potential issues ?

Multiplexed gene editing & CAR-T cells: potential issues ? In the Stem Cell Jungle

78 views - 4 years ago

Managing T cell exhaustion: Lowering CAR expression level for greater efficacy ?

Managing T cell exhaustion: Lowering CAR expression level for greater efficacy ? In the Stem Cell Jungle

163 views - 4 years ago

CAR-T cells: the challenges of targeting solid tumors

CAR-T cells: the challenges of targeting solid tumors In the Stem Cell Jungle

140 views - 4 years ago

CAR-T cell therapy associated toxicities : B-cell aplasia, not an issue for patients ?

CAR-T cell therapy associated toxicities : B-cell aplasia, not an issue for patients ? In the Stem Cell Jungle

149 views - 4 years ago

Lessons learned from the first generation of CAR-T cells

Lessons learned from the first generation of CAR-T cells In the Stem Cell Jungle

71 views - 4 years ago

From Gene Editing to CAR-T cells, an insider view on the journey of Cellectis

From Gene Editing to CAR-T cells, an insider view on the journey of Cellectis In the Stem Cell Jungle

121 views - 4 years ago

The dream of a gene editing expert: efficient knock-ins in T & NK cells

The dream of a gene editing expert: efficient knock-ins in T & NK cells In the Stem Cell Jungle

81 views - 4 years ago